Here's What Analysts Are Saying About Taysha Gene Therapies (TSHA) [Yahoo! Finance]
Taysha Gene Therapies, Inc. (TSHA)
Company Research
Source: Yahoo! Finance
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) on January 6, reiterating a Buy rating on the stock with a $10 price target. The rating update came the same day Taysha Gene Therapies, Inc. (NASDAQ:TSHA) announced the dosing of the first patient in the REVEAL pivotal trial evaluating TSHA-102 in Q4 2025, with enrollment advancing across multiple sites. It reported progress across the TSHA-102 pivotal program, an intrathecally delivered AAV9 gene therapy with disease-modifying potential, in clinical evaluation for the treatment of Rett syndrome. The company also stated that it reached written alignment with the FDA regarding the inclusion of =3 months of safety data from the ASPIRE trial evaluating TSHA-102 in the planned BLA submission to support a broad label in patients aged =2 years with Rett syndrome. Dosing in the REVEAL pivotal trial and ASPIRE trial is anticipated to be completed in Q2 2026, with the longer-term safety and efficacy data update from Part A of REVEAL Phase 1/2 trials
Show less
Read more
Impact Snapshot
Event Time:
TSHA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TSHA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TSHA alerts
High impacting Taysha Gene Therapies, Inc. news events
Weekly update
A roundup of the hottest topics
TSHA
News
- Taysha Gene Therapies, Inc. (TSHA) Gains Wells Fargo's Support on Rett Syndrome Program Progress [Yahoo! Finance]Yahoo! Finance
- Taysha Gene Therapies Inc. (TSHA): A Promising Biotech on Rett Syndrome Drug Prospects [Yahoo! Finance]Yahoo! Finance
- Taysha Gene Therapies (NASDAQ:TSHA) had its "strong-buy" rating reaffirmed by analysts at Raymond James Financial, Inc..MarketBeat
- Taysha Gene Therapies (NASDAQ:TSHA) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.MarketBeat
- Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett SyndromeGlobeNewswire
TSHA
Earnings
- 11/4/25 - In-Line
TSHA
Sec Filings
- 2/5/26 - Form SCHEDULE
- 2/4/26 - Form 144
- 2/4/26 - Form 144
- TSHA's page on the SEC website